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Background: Due to improvements in early detection, treatment, and supportive care, the number of colorectal
cancer (CRC) survivors is increasing; therefore, careful attention should always be paid to the second primary cancer
(SPC) in treating these CRC patients. The present study attempts to determine the correlation and clinical aspects of
CRC to other cancers in patients suffering from SPC involving CRC.
Methods: From January 2002 and June 2010, 1,679 cancer cases, CRC was accompanied by SPC in 89 patients
(5.3%), including 16 (18%) synchronous and 73 (82%) metachronous SPC patients. These patients were subsequently
classified into two groups: the first group had CRC diagnosed first as CRC first (CRCF); and the second group had
another type of cancer diagnosed before the diagnosis of CRC as other cancer first (OCF). Of these 73 patients, 22
(30.1%) were in the group of CRCF, whereas 51 (69.9%) were in the group of OCF. Patients’ clinicopathological
characteristics and clinical outcomes were analyzed and compared between the two groups.
Results: There was a significant difference in the sites of cancers between the two groups: 14 (27.5%) patients in
the OCF group had gastric cancer, compared to one (4.5%) patient in the CRCF group (P = 0.026). Although there
was no difference of hepatitis B virus (HBV) or hepatitis C virus (HCV) carriers between the OCF and CRCF groups
(P = 0.165), there were six (27.3%) CRC patients with hepatocellular carcinoma (HCC) in the CRCF group, which was
significantly higher than the two (3.9%) patients in the OCF group (P = 0.003). Furthermore, the cancer-specific
survival rate of the CRCF patient group was significantly higher than that of the OCF patient group (P = 0.036).
Conclusions: In this retrospective analysis, gastric cancer patients compared to other secondary cancers were at a
higher risk of developing subsequent CRC as SPC; alternatively, patients with CRC were at a higher risk of
developing HCC as SPC subsequently, no matter whether patients were HBV or HCV carriers. Therefore, careful
attention should always be paid to the possibility of secondary CRC to construct effective surveillance when
treating cancer patients.
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Colorectal cancer (CRC) is the second leading cause of
cancer-related mortality in Europe and the USA, and
there are approximately 300,000 new cases and 200,000
deaths due to CRC in these areas annually [1,2]. It has
been reported that the incidence of CRC in economically
transitioning countries continues to rise and the inci-
dence of CRC in economically developed countries has
stabilized or is declining [3]. In Taiwan, CRC was the
third leading cause of cancer death and the death rate
was 20.2 per 100,000 in 2010 (http://www.mohw.gov.tw/
cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=2622;
accessed in Auguest 2012). There was a 24.69% increase
in the CRC-related death rate in 2010 compared with
that in 2002 and a 64.23% increase compared with that
in 1996 [1]. In Taiwan, cancer is reported as the first
leading cause of death and the death rate was 177.40 per
100,000 in 2010, over eight times the European and USA
average. There was a 16.02% increase in the cancer death
rate in 2010 compared with that in 2002 and a 36.04%
increase compared with that in 1996 (http://www.mohw.
gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=
2622; accessed in Auguest 2012). Cancer patients are at
high risk of developing a second cancer after the treat-
ment of the initial cancer [1,4,5]. Due to improvements
in early detection, supportive care, and multimodality
treatments, the number of CRC survivors has increased
in recent decades, and continuing careful attention
should always be paid to the second primary cancer
(SPC) in treating these CRC patients.
In recent years, reports have documented that the
present percentage of SPC in the total number of can-
cers ranges from 0.73% to 11.70% [6] and the trend is in-
creasing [5,7]. Compared with the general population,
patients with CRC are at a higher risk of developing a
SPC [8]. Thus, it is important to be aware of the clinical
characteristics of SPC in CRC patients for early diagno-
sis and effective treatment. Several analytical studies
have found interesting associations between the first
tumor site and the subsequent tumors; this could be
useful for prevention [9-11]. The initial characteristics of
CRC as well as possible risk factors for subsequent SPC
are also crucial for clinicians [12,13]. However, no rele-
vant information regarding the differences between the
sequences of CRC or SPC occurrence is available up to
the present time.
In this retrospective analysis, CRC patients with at
least two primary malignancies were analyzed with re-
gard to differences of clinicopathological features and
survival (CRC first or other malignancy first). We tried
to identify potential risk factors and clinical outcomes
which could possibly evaluate, describe, and provide ap-
propriate postoperative surveillance strategies for CRC
patients and furthermore, identify early SPC.Methods
Patients
This retrospective cohort study included 1,679 consecu-
tive patients with histologically proven CRC who re-
ceived surgical treatment at the Department of Surgery
at Kaohsiung Medical University Hospital, Kaohsiung,
Taiwan, from January 2002 to December 2010. The in-
clusion criteria were that each tumor had to have a
definite histological picture of primary CRC and the
probability that one was a metastatic lesion from the
other organ must be excluded [11]. Of 1,679 cancer
cases, CRC was accompanied by SPC in 89 patients
(5.3%), including 16 (18%) synchronous and 73 (82%)
metachronous SPC. SPC detected within 6 months after
the initial cancers were regarded as synchronous can-
cers, and the others were categorized as metachronous
cancers [10]. Therefore, 16 synchronous cancer patients
were excluded for the subsequent analysis. The patients
were classified into two groups: one group had CRC di-
agnosed first as CRC first (CRCF); and the other group
had another type of cancer diagnosed before the diagno-
sis of CRC as other cancer first (OCF).
Patients’ clinicopathological characteristics were ana-
lyzed. Available variables included: age of onset, gender,
tumor location, histological type, TNM classification of
malignant tumors (TNM) defined according to the cri-
teria of the American Joint Commission on Cancer/
Union for International Cancer Control (AJCC/UICC)
[14], vascular invasion, perineural invasion, preoperative
serum level of albumin, preoperative serum level of car-
cinoembryonic antigen (CEA), comorbidity of cardiac
disease, administration of chemotherapy, and body mass
index (BMI). Preoperative serum levels of albumin and
CEA were checked within 1 week before operation. The
normal cut-off values of serum albumin and CEA were
defined as 3.5 gm/dL and 5 ng/mL, respectively. We
reviewed all patients’ charts to identify the presence of
secondary cancers. Patient clinical outcomes and sur-
vival status were regularly followed up until their last
visit or death, or if the patient was lost to follow-up. This
present study is a retrospective cohort study by analysis
from medical records, it dose not need patients' ICF ac-
cording to Taiwan local IRB regulation after approval of
the Institutional Review Board of the Kaohsiung Medical
University Hospital. (KMUH-IRB-990361).
Statistical analysis
All data were statistically analyzed using IBM SPSS Sta-
tistics, version 17.0 (IBM Corporation, Armonk, NY,
USA). For the univariate statistical analysis, chi-square
test and student t-test were used where applicable for cat-
egorical and continuous variables, respectively. Cancer-
specific and overall survival rates were calculated by the
Kaplan −Meier method, and the differences in survival
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than 0.05 was considered to be statistically significant.
Results
The clinical and pathological data regarding CRC pa-
tients diagnosed with SPC are summarized in Table 1.Table 1 Clinicopathological characteristics of 73 second
primary cancer (SPC) patients



































aRight colon: cecum, ascending colon, and transverse colon; left colon:
descending colon and sigmoid colon. BMI, body mass index; CEA,
carcinoembryonic antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; MD,
moderately differentiated; PD, poorly differentiated; SPC, second primary
cancer; TNM, TNM classification of malignant tumors; WD, well differentiated.There were 73 (4.3%) patients diagnosed with metachro-
nous SPC. Sixty-eight (93.2%) patients had double can-
cers and five (6.8%) patients suffered from triple cancers.
Of these 73 patients, 22 (30.1%) were in the group of
CRCF, whereas 51 (69.9%) were in OCF. There were also
no significant differences in gender, tumor size, tumor
location, histological type, AJCC/UICC cancer stage, vas-
cular invasion, perineural invasion, BMI, and comorbid-
ity of pulmonary disease and renal disease. Meanwhile,
the percentages of patients receiving adjuvant chemo-
therapy were not significantly different in the two groups
(P = 0.206; Table 2). The mean age at the time of diagno-
sis of the first cancer was 64.0 years in the CRCF group
and 58.0 years in OCF patients. Likewise, the mean age
at the time of the second cancer between the two groups
was not significantly different (67.0 ± 12.0 versus 66.9 ±
13.6). Between the first and second cancer there is a
time lag of approximately 2.9 years in the CRCF group
and 8.7 years in the OCF group, which was significantly
different (P = 0.002; Table 2).
Table 3 shows the sites of the SPCs. In the 15 sites of
SPC, gastric cancer, breast cancer, bladder cancer, and
hepatocellular carcinoma (HCC) were most frequently
detected, followed by cancers in the lung. The most fre-
quent site of cancers in the group of OCF was gastric
cancer, and the most frequent site of cancers in the
group of CRCF were HCC and ovarian cancer. There
was a significant difference in the sites of cancers in
these two groups: 14 (27.5%) patients in the OCF group
had gastric cancer compared to one (4.5%) patient in the
CRCF group (P = 0.026). The comparison stage data of
15 gastric cancer patients and eight HCC patients between
CRCF and OCF was not significantly different (P = 0.232
versus P = 0.587; Tables 4 and 5). Although there was no
difference of hepatitis B virus (HBV) or hepatitis C virus
(HCV) carriers between the OCF and CRCF (P = 0.165), a
measure of six (27.3%) of 22 CRC patients with HCC as
SPC in the CRCF group was significantly higher than two
(3.9%) of 51 patients in the OCF group (P = 0.003). There
was a significant difference in the sites of cancers in these
two groups: no patients in the OCF group had ovarian
cancer compared to two (9.1%) patients in the CRCF
group (P = 0.029).
Regarding survival analysis, the cancer-specific survival
of CRCF patients was significantly higher than that of
the OCF patient group (P = 0.036; Figure 1A), but overall
survival of CRCF patients was not significantly different
between the two groups (P = 0.108; Figure 1B).
Discussion
Cancer-bearing patients are assumed to have an in-
creased incidence of developing cancer of other organs
[15]. In this current investigation, we identified that 5.3%
of CRC patients were diagnosed with SPC, which was
Table 2 Clinicopathological characteristics of 73 second primary cancer (SPC) patients by other cancer first (OCF) and
colorectal cancer first (CRCF)
Parameters OCF (%) CRCF (%) P value
N = 51 (69.9) N = 22 (30.1)
Gender
Male/Female 23 (45.1)/28 (54.9) 11 (50.0)/11 (50.0) 0.700
Age (years)
<65/≥65 21 (41.2)/30 (58.8) 10 (45.5)/12 (54.5) 0.734
Interval diagnosis time (years) 8.7 ± 8.32 2.9 ± 1.98 0.002
HBV and HCV carrier
Yes/No 7 (13.7)/44 (86.3) 6 (27.3)/16 (72.7) 0.165
BMI (kg/m2)
<22/≥22 24 (47)/27 (53) 10 (45.5)/12 (54.5) 0.916
Albumin (gm/dL)
<3.5/≥3.5 24 (47)/27 (53) 8 (36.3)/14 (63.7) 0.390
Tumor size (cm)
≥5/<5 23 (45.1)/28 (54.9) 6 (27.3)/16 (72.7) 0.136
Tumor locationa 0.158
Right colon 15 (29.4) 3 (13.6)
Left colon 25 (49.0) 10 (45.5)
Rectum 11 (21.6) 9 (40.9)
TNM stage
III + IV/I + II 26 (51)/25 (49) 9 (40.9)/13 (59.1) 0.429
Vascular invasion
Yes/No 16 (31.4)/35 (68.6) 8 (36.4)/14 (63.6) 0.632
Perineurial invasion
Yes/No 18 (35.3)/33 (64.7) 4 (18.2)/18 (81.8) 0.159
Histology type
PD/WD +MD 6 (11.8)/45 (88.2) 2 (9.1)/20 (90.9) 0.864
Depth
T3 + T4/T1 + T2 43 (84.3)/8 (15.7) 17 (77.3)/5 (22.7) 0.635
Lymph Node
N1 + N2/N0 23 (43.1)/28 (54.9) 8 (36.4)/14 (63.6) 0.488
Pre-operation CEA (ng/mL)
≥5/<5 25 (49)/26 (51) 14 (63.6)/8 (36.4) 0.226
Chemotherapy
Yes/No 27 (52.9)/24 (47.1) 15 (68.2)/7 (31.8) 0.206
Diabetes mellitus
Yes/No 11 (21.6)/40 (78.4) 4 (18.2)/18 (81.8) 0.742
Cardiac disease
Yes/No 5 (9.8)/46 (90.2) 4 (18.2)/18 (81.8) 0.318
aRight colon: cecum, ascending colon, and transverse colon; left colon: descending colon and sigmoid colon. BMI, body mass index; CEA, carcinoembryonic
antigen; CRCF, colorectal cancer first; HBV, hepatitis B virus; HCV, hepatitis C virus; MD, moderately differentiated; OCF, other cancer first; PD, poorly differentiated;
SPC, second primary cancer; TNM, TNM tumor node metastasis; WD, well differentiated.
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0.73% and 11.70%) [6], and the trend has been increasing
in recent reports [5,7]. The most frequent sites ofcancers preceding or following CRC were as follows:
gastric cancer, breast cancer, bladder cancer, and HCC.
In Western studies, however, different combinations of
Table 3 Site distribution of second primary cancers (SPCs)
in patients with other cancer first (OCF) and colorectal
cancer first (CRCF)
Parameters OCF (%) CRCF (%) P value
(N = 51) (N = 22)
Gastric cancer 14 (27.5) 1 (4.5) 0.026
Hepatocellular carcinoma (HCC) 2 (3.9) 6 (27.3) 0.003
Breast cancer 10 (19.6) 2 (9.1) 0.266
Prostate cancer 2 (3.9) 0 (0) 0.346
Cervical cancer 3 (5.9) 0 (0) 0.245
Ovarian cancer 0 (0) 2 (9.1) 0.029
Bladder cancer 4 (7.8) 4 (18.2) 0.194
Lung cancer 2 (3.9) 2 (9.1) 0.373
Thyroid cancer 5 (9.8) 0 (0) 0.128
Nasal pharyngeal cancer 4 (7.8) 0 (0) 0.177
Lymphoma 2 (3.9) 1 (4.5) 0.902
Oral cancer 3 (5.9) 1 (4.5) 0.818
Gallbladder cancer 0 (0) 1 (4.5) 0.125
Thymus cancer 0 (0) 1 (4.5) 0.125
Brain cancer 0 (0) 1 (4.5) 0.125
HBV and HCV carrier 7 (13.7) 6 (27.3) 0.165
CRCF, colorectal cancer first; HBV, hepatitis B virus; HCV, hepatitis C virus; OCF,
other cancer first; SPC, second primary cancer.
Table 5 Comparison stage of hepatocellular carcinoma
(HCC) between other cancer first (OCF) and colorectal
cancer first (CRCF)
Parameters OCF (%) CRCF (%) P value
N = 2 (25) N = 6 (75)
TNM stage I 0 (0) 1 (100) 0.587
TNM stage II 1 (50) 0 (0)
TNM stage III 1 (50) 0 (0)
TNM stage IV 0 (0) 0 (0)
CRCF, colorectal cancer first; HCC, hepatocellular carcinoma; OCF, other cancer
first; TNM, TNM classification of malignant tumors.
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likely due to the low incidence of gastric cancer in Western
populations.
Of the 51 cases in the OCF group, the stomach was
the most frequent site before developing CRC as SPC.
Ueno et al. indicated that when colon cancer was com-
bined with other cancers, stomach cancer (1.4%) was the
most frequently encountered neoplasm, followed by
breast cancer (0.4%); and when rectal cancer was com-
bined with other cancers, stomach cancer (0.6%) was
also the most frequently encountered neoplasm, but this
was followed by lung cancer (0.5%) [4]. Consequently,
they suggested close follow-up to ascertain the possibil-
ity of developing secondary CRC among gastric cancer
patients postoperatively. Our results are consistent withTable 4 Comparison stage of gastric cancer between
other cancer first (OCF) and colorectal cancer first (CRCF)
Parameters OCF (%) CRCF (%) P value
N = 14 (93.3) N = 1 (6.7)
TNM stage I 2 (14.3) 1 (100) 0.232
TNM stage II 4 (28.6) 0 (0)
TNM stage III 3 (21.4) 0 (0)
TNM stage IV 5 (35.7) 0 (0)
CRCF, colorectal cancer first; OCF, other cancer first; TNM, TNM classification of
malignant tumors.this study, since the most frequent SPC after gastric can-
cer was CRC. Therefore, colonoscopic examination
should be arranged for the possibility of CRC in treating
gastric cancer patients if they have hematochezia or
ileus, in order to detect synchronous or metachronous
CRC [13]. On the other hand, the liver was the most
common site in CRC patients who developed SPC in the
present study; however, gastric cancer remains the most
frequent SPC in CRC patients from a Japanese study [4].
Despite there being no difference of HBV or HCV car-
riers between the OCF and CRCF, the incidence of HCC
as SPC in the CRCF group was significantly higher than
that in the OCF group. Patients with CRC were at a high
risk of developing HCC as SPC, no matter whether the
patients were HBV or HCV carriers. Follow-up strategies
such as abdominal echo or computed tomography (CT)
are also needed for these CRC patients to detect primary
or metastatic liver lesions.
Likewise, in this study, the incidence of lung cancer to-
gether with CRC was only 0.5%, which is close to the re-
sult of the Japanese study [4]. Another study from
Taiwan observed that the most common SPC in CRC
patients was the liver, followed by the stomach [16]. In
our study, HCC is ranked as the third leading SPC.
However, only 1.26% of patients developed SPCs in an-
other study from northern Taiwan [16]. A significantly
higher proportion of Dukes’ B patients developed SPC
than that of patients of other stages [16]. In our study,
nine (0.53%) of TNM stage II patients developed SPC,
which was not significantly different from other stages.
Birgisson et al. reveals that inclusion of SPC affects the
results of cancer-specific survival rates in patients with
CRC [17]. SPC generates a significant number of events
during follow-up of patients with CRC, which causes
worse cancer-specific survival rates when SPC is in-
cluded as an event in the calculations. Almost half as
many SPC cases were observed as endpoints as death
from the same cancer or non-cancer-related deaths [17].
For women diagnosed with both breast cancer and CRC,
the cumulative risk of death at 5 years following the sec-
ond cancer diagnosis is three times more likely to be
Figure 1 Cumulative survival rates of second primary cancer (SPC) in colorectal cancer (CRC) patients. (A) Cumulative cancer-specific
survival rates of SPC in CRC patients. Better survival was observed in the colorectal cancer first (CRCF) group (P = 0.036). (B) Cumulative overall
survival rates of SPC in CRC patients. No significant differences were observed between the CRCF and other cancer first (OCF) group (P = 0.108).
CRC, colorectal cancer; CRCF, colorectal cancer first; OCF, other cancer first; SPC, second primary cancer.
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cancer-specific survival rate of CRCF patients was sig-
nificantly higher than that of the OCF patients. The
study by Tsai et al. suggests that perineural invasion may
be a significant factor for postoperative early relapse ofcolon cancer and significantly lower overall survival rates
in CRC patients [19]. Despite the cancer-specific survival
rate being higher in the CRCF group, the overall survival
was not significantly different between the CRCF and
OCF groups in our study, and this might result from the
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after 8 years of follow-up). The event that occurred most
often in patients treated with curative intention was
non-cancer-related death [18].
We are left, finally, with several caveats: 1) there are
few (if any) prospective controlled trials of screening
strategies among patients who are at risk for second ma-
lignancies that can guide us with objective, evidence-
based information about appropriate screening and
management for patients with primary malignancies; 2)
there is very little validated evidence that an increased
screening frequency will improve outcomes among pa-
tients who develop second malignancies; and 3) the opti-
mal screening modalities and strategies for patients who
are at risk for second malignancies remain to be defined
for most tumor sites. Additional investigative efforts in
the future should strive to address these limitations in
our current knowledge.
Conclusion
In summary, SPC in CRC remains a difficult issue for
clinicians no matter whether in CRCF or OCF. In
addition to a regular follow-up program, for the variety
of different sites of SPC, clinicians must pay more atten-
tion to determining the potential lesions especially for
the accompanying high incidence of malignancies.
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